Translator Disclaimer
May 2010 Bayesian Models and Decision Algorithms for Complex Early Phase Clinical Trials
Peter F. Thall
Statist. Sci. 25(2): 227-244 (May 2010). DOI: 10.1214/09-STS315


An early phase clinical trial is the first step in evaluating the effects in humans of a potential new anti-disease agent or combination of agents. Usually called “phase I” or “phase I/II” trials, these experiments typically have the nominal scientific goal of determining an acceptable dose, most often based on adverse event probabilities. This arose from a tradition of phase I trials to evaluate cytotoxic agents for treating cancer, although some methods may be applied in other medical settings, such as treatment of stroke or immunological diseases. Most modern statistical designs for early phase trials include model-based, outcome-adaptive decision rules that choose doses for successive patient cohorts based on data from previous patients in the trial. Such designs have seen limited use in clinical practice, however, due to their complexity, the requirement of intensive, computer-based data monitoring, and the medical community’s resistance to change. Still, many actual applications of model-based outcome-adaptive designs have been remarkably successful in terms of both patient benefit and scientific outcome. In this paper I will review several Bayesian early phase trial designs that were tailored to accommodate specific complexities of the treatment regime and patient outcomes in particular clinical settings.


Download Citation

Peter F. Thall. "Bayesian Models and Decision Algorithms for Complex Early Phase Clinical Trials." Statist. Sci. 25 (2) 227 - 244, May 2010.


Published: May 2010
First available in Project Euclid: 19 November 2010

zbMATH: 1328.62597
MathSciNet: MR2789992
Digital Object Identifier: 10.1214/09-STS315

Rights: Copyright © 2010 Institute of Mathematical Statistics


Vol.25 • No. 2 • May 2010
Back to Top